Gufic Biosciences Limited reported a consolidated net profit of ₹642.15 crore for the financial year ended March 31, 2026, a decrease from ₹696.50 crore in the previous year. Revenue from operations for the year rose to ₹9,440.07 crore, compared to ₹8,198.06 crore in FY25. The Board of Directors, meeting on May 29, 2026, approved the audited standalone and consolidated financial results and recommended a final dividend of 10%, or Re. 0.10 per equity share having a face value of Re. 1 each, subject to shareholder approval at the ensuing Annual General Meeting.

For the quarter ended March 31, 2026, the company recorded a consolidated net profit of ₹21.90 crore, a significant increase from ₹7.72 crore in the same quarter of the previous year. Quarterly revenue stood at ₹251.82 crore, up from ₹205.02 crore in Q4FY25. The Statutory Auditors, M/s. Mittal Agarwal & Co., issued an unmodified opinion on the financial results.

Key Financial Highlights

The Board also approved the re-appointment of M/s. Poddar & Co., Cost Accountants, for FY27 and appointed Mrs. Saroj R. Kirdolia as the Internal Auditor effective from the financial year 2026-27. Additionally, the company sanctioned a further investment of ₹5.75 crore in Saraswat Co-operative Bank Limited by subscribing to 57,50,800 equity shares at a face value of ₹10 each.

The company amended its Code of Conduct for Directors and Senior Management Personnel to align with the Companies Act, 2013, and Listing Regulations. The meeting was held in compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Gufic Biosciences Limited has approved a further investment of ₹5.75 crore in Saraswat Co-operative Bank Limited to strengthen its existing banking relationship and support its treasury management strategy. The Board of Directors approved the subscription to 57,50,800 equity shares at a face value of ₹10 each during a meeting held on May 29, 2026. This strategic investment is expected to enhance the company's banking engagement and provide potential long-term benefits through investment appreciation and dividend income.

The transaction does not fall under related party transactions, and the promoter or promoter group has no interest in the acquisition. The company currently holds 7,500 equity shares in the bank, which will increase to 57,58,300 shares post-acquisition. The consideration for the acquisition will be paid in cash, and the entire process is slated for completion within four months.

Saraswat Co-operative Bank, incorporated in 1918, operates as a scheduled bank offering a suite of banking and financial services, including retail and wholesale banking and treasury operations. As of March 31, 2025, the bank reported a total income of ₹5064.53 crore and a net worth of ₹5484.91 crore. The bank's total subscribed capital stands at 32,01,75,196 shares of ₹10 each.

The investment aligns with Gufic Biosciences' regular utilisation of banking and credit facilities from Saraswat Bank for its business operations and expansion requirements. The company stated that the subscription to additional equity shares is in line with its existing credit exposure and broader investment strategy.

Financials of Saraswat Co-operative Bank